U.S. markets closed
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • Dow 30

    34,200.67
    +164.68 (+0.48%)
     
  • Nasdaq

    14,052.34
    +13.58 (+0.10%)
     
  • Russell 2000

    2,262.67
    +5.60 (+0.25%)
     
  • Crude Oil

    63.07
    -0.39 (-0.61%)
     
  • Gold

    1,777.30
    +10.50 (+0.59%)
     
  • Silver

    26.04
    +0.08 (+0.29%)
     
  • EUR/USD

    1.1980
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • GBP/USD

    1.3840
    +0.0056 (+0.41%)
     
  • USD/JPY

    108.7830
    +0.0670 (+0.06%)
     
  • BTC-USD

    56,162.84
    -6,087.25 (-9.78%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.68 (+0.14%)
     

Will Trikafta Drive Vertex's (VRTX) Revenues in Q4 Earnings?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

We expect Vertex Pharmaceuticals Incorporated VRTX to surpass expectations when it reports fourth-quarter and full-year 2020 results on Feb 1, after market close.

The company’s earnings surprise record is pretty impressive. It delivered an earnings beat in each of the trailing four quarters, the average being 28.35%. In the last-reported quarter, Vertex delivered an earnings surprise of 10.46%.

Shares of Vertex have lost 3.1% in the past year against the industry’s increase of 16.6%.

price chart for VRTX
price chart for VRTX


Let’s see how things have shaped up for the quarter to be reported.

Factors at Play

Revenue growth in the last-reported quarter was driven by a rapid uptake of the company’s new cystic fibrosis (“CF”) medicine Trikafta– a trend that is most likely to have continued in the fourth quarter.

Notably, in August 2020, the European Commission (“EC”) approved Kaftrio (brand name of Trikafta in Europe). Following the nod from the EC, about 10,000 new patients with one minimal function mutation and one F508del mutation are now eligible to be treated with Kaftrio. The approval in Europe is most likely to have contributed to international revenues in the fourth quarter.

The strong acceptance of Trikafta caused the sales erosion of Vertex’s other CF drugs and its existing combinations, namely Kalydeco, Orkambi and Symdeko/Symkevi. In the last-reported quarter, all the other three CF medicines saw a year-over-year decline in sales, a trend that most likely continued in the to-be-reported quarter as well.

Meanwhile, in December 2020, the FDA approved Trikafta, Symdeko and Kalydeco for additional rare cystic fibrosis transmembrane conductance regulator mutations. These approvals will help to treat additional 600 CF patients.

Please note that the approval of Trikafta/Kaftrio in additional geographies, reimbursement agreements for Kaftrio in EU countries, and approval of all CF medicines for younger patient populations and additional mutations could bring additional revenues for Vertex in the fourth quarter and beyond.

Why a Likely Positive Surprise?

Our proven model predicts an earnings beat for Vertex this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Earnings ESP: Vertex has an Earnings ESP of +5.39% as the Zacks Consensus Estimate is pegged at $2.65 while the Most Accurate Estimate is pegged at $2.80.

Zacks Rank: Vertex has a Zacks Rank #2

Vertex Pharmaceuticals Incorporated Price and Consensus

Vertex Pharmaceuticals Incorporated Price and Consensus
Vertex Pharmaceuticals Incorporated Price and Consensus


Vertex Pharmaceuticals Incorporated price-consensus-chart | Vertex Pharmaceuticals Incorporated Quote

Other Stocks to Consider

Here are some other drug/biotech stocks worth considering from the same space as our model shows that these too have the right combination of elements to beat on earnings this reporting cycle.

Alexion Pharmaceuticals, Inc. ALXN has an Earnings ESP of +12.29% and a Zacks Rank of 2, currently. The company is scheduled to report earnings on Feb 4.

Alkermes plc ALKS has an Earnings ESP of +21.74% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Gilead Sciences, Inc. GILD has an Earnings ESP of +3.89% and a Zacks Rank of 3, currently. The company is scheduled to report earnings on Feb 4.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot stocks we're targeting >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alkermes plc (ALKS) : Free Stock Analysis Report

Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research